Drug
Aav Cngb3
Aav Cngb3: highest development phase Phase 1/2, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV - CNGB3 NCT03001310 | Phase 1/2 | Achromatopsia |
Latest
No recent events.
Follow Aav Cngb3 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.